The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Official Title: A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Study ID: NCT00915278
Brief Summary: Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Tooting, London, United Kingdom
Pfizer Investigational Site, North Cheam, Surrey, United Kingdom
Pfizer Investigational Site, Sutton, Surrey, United Kingdom
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR